Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.58 |
| ▸ | JAK2 | O60674 | 5/20 | 0.58 |
| ▸ | JAK1 | P23458 | 5/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918564 | 1.00 | JAK3 (0.58) | JAK3JAK2JAK1KCNH2LCK | |
| SCHEMBL9918565 | 1.00 | JAK3 (0.58) | JAK3JAK2JAK1KCNH2LCK | |
| SCHEMBL9918473 | 0.88 | JAK3 (0.67) | JAK3JAK2JAK1KCNH2TYK2 | |
| SCHEMBL9918475 | 0.88 | JAK3 (0.67) | JAK3JAK2JAK1KCNH2TYK2 | |
| SCHEMBL9921988 | 0.88 | JAK3 (0.67) | JAK3JAK2JAK1KCNH2TYK2 | |
| SCHEMBL9918660 | 0.81 | JAK3 (0.57) | JAK3JAK2JAK1LCKTYK2 | |
| SCHEMBL9918568 | 0.78 | JAK3 (0.50) | JAK3JAK2JAK1LCKTYK2 | |
| SCHEMBL12832701 | 0.78 | JAK3 (0.54) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL9918569 | 0.77 | JAK3 (0.47) | JAK3JAK2JAK1KCNH2 | |
| SCHEMBL9918571 | 0.75 | JAK3 (0.37) | JAK3JAK2JAK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK3 3/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.